SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: IRWIN JAMES FRANKEL1/6/2006 10:25:21 AM
  Read Replies (2) of 1826
 
10:22 MOGN MGI Pharma downgraded to Mkt Perform at Leerink Swan before the open (17.67 -0.16)

Before the open, Leerink Swan downgraded MOGN to Mkt Perform from Outperform and lowereed their valuation range to $19-22. They say two recent MEDACorp surveys suggest the growth of lead product Aloxi may be challenging in 2006-07 and the initial uptake of lead pipeline candidate Dacogen could be modest. They say that after the arrival of generic Zofran in late '06, physicians projected declining shares of Aloxi for 2007. While they believe the survey may have overstated the impact of generic Zofran, they see modest Aloxi growth in '06 and especially '07.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News